CARDIONATE IN COMBINED THERAPY OF ISCHEMIC CHRONIC HEART FAILURE AMONG PATIENTS WITH METABOLIC SYNDROME

Abstract

This 12-week study included 60 patients (age 45-65 years) with metabolic syndrome (MS), chronic heart failure (CHF) of II-III functional class (FC), and recent myocardial infarction. The participants were randomised into two groups (n=30 for each). In the main group, standard CHF therapy was combined with Cardionate 1,0 g/d (meldonium, Makiz-Pharma, Russia). Cytoprotector Cardionate, as a part of complex CHF therapy in MS patients, improved CHF FC and exercise capacity, increased left ventricular (LV) ejection fraction, normalised LV myocardial structure and function, and improved renal function, also reducing insulin resistance severity and improving lipid and carbohydrate metabolism.

Keywords

• metabolic syndrome
• chronic heart failure
• cardionate
• insulin resistance
• carbohydrate and lipid metabolism